XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Revenues (Tables)
 3 Months Ended
Mar. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Revenues consisted of the following (in thousands):
Three Months Ended March 31,
20232022
Product revenues:
Gross product revenues$521,322 $448,237 
Discounts and allowances(157,922)(137,939)
Net product revenues363,400 310,298 
Collaboration revenues:
License revenues38,292 32,067 
Collaboration services revenues7,096 13,615 
Total collaboration revenues45,388 45,682 
Total revenues$408,788 $355,980 
Net product revenues by product were as follows (in thousands):
Three Months Ended March 31,
20232022
CABOMETYX$361,773 $302,812 
COMETRIQ1,627 7,486 
Net product revenues$363,400 $310,298 
Schedule of Concentration Risks
The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
Three Months Ended March 31,
20232022
Affiliates of McKesson Corporation17 %19 %
Affiliates of CVS Health Corporation17 %17 %
Affiliates of AmerisourceBergen Corporation17 %17 %
Accredo Health, Incorporated12 %9 %
Affiliates of Optum Specialty Pharmacy10 %10 %
Ipsen Pharma SAS8 %10 %
The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
March 31, 2023December 31, 2022
Affiliates of McKesson Corporation24 %22 %
Affiliates of AmerisourceBergen Corporation19 %18 %
Ipsen Pharma SAS18 %20 %
Affiliates of CVS Health Corporation13 %18 %
Cardinal Health, Inc.9 %11 %
Schedule of Revenues Disaggregated by Geographic Region
Revenues by geographic region were as follows (in thousands):
Three Months Ended March 31,
20232022
U.S.$367,441 $314,065 
Europe33,534 34,527 
Japan7,813 7,388 
Total revenues$408,788 $355,980 
Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances
The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
Chargebacks, Discounts for Prompt Payment and Other
Other Customer Credits/Fees and Co-pay Assistance
Rebates
Total
Balance at December 31, 2022
$26,881 $14,924 $35,426 $77,231 
Provision related to sales made in:
Current period94,959 14,913 49,113 158,985 
Prior periods141 (1,117)(87)(1,063)
Payments and customer credits issued(100,831)(13,637)(33,130)(147,598)
Balance at March 31, 2023
$21,150 $15,083 $51,322 $87,555 
Schedule of Other Assets and Other Liabilities Contract assets and liabilities were as follows (in thousands):
March 31, 2023December 31, 2022
Contract assets (1)
$1,387 $1,659 
Contract liabilities:
Current portion (2)
$7,064 $7,488 
Long-term portion (3)
6,299 6,582 
Total contract liabilities$13,363 $14,070 
____________________
(1) Presented in other long-term assets in the accompanying Condensed Consolidated Balance Sheets.
(2) Presented in other current liabilities in the accompanying Condensed Consolidated Balance Sheets.
(3) Presented in the long-term portion of deferred revenues in the accompanying Condensed Consolidated Balance Sheets.